Company intelligence / Profile preview
Respira Therapeutics
Santa Fe, New Mexico, United Statesrespiratherapeutics.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
RT234-PAH demonstrated robust safety margins in preclinical testing and was well tolerated in Phase 1 clinical studies, with pharmacokinetic profiles consistent with expectations for a PRN medication. Currently in Phase 2 clinical testing.[3]
- Therapeutic areas
- Cardiovascular
- Modalities
- Inhaled therapeuticsDry-powder formulations
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Respira Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Respira Therapeutics.